<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764814</url>
  </required_header>
  <id_info>
    <org_study_id>P014-03</org_study_id>
    <nct_id>NCT02764814</nct_id>
  </id_info>
  <brief_title>In Vivo Confocal Microscopic Analysis of Corneal Nerve Changes After ProKera Slim® for Dry Eye</brief_title>
  <official_title>In Vivo Confocal Microscopic Analysis of Corneal Nerve Changes After ProKera Slim® for Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tissue Tech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tissue Tech Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective controlled pilot study to compare the outcome of ProKera® (PK) and conventional
      treatment in patients with moderate to severe Dry Eye Disease (DED)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term efficacy in terms of corneal nerve regeneration</measure>
    <time_frame>Change from Baseline to 1 month</time_frame>
    <description>Assessed by corneal topography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term efficacy in terms of ocular surface integrity</measure>
    <time_frame>Change from Baseline to 1 month</time_frame>
    <description>Assessed by in vivo confocal microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term efficacy in terms of corneal sensitivity</measure>
    <time_frame>Change from Baseline to 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Short-term efficacy in terms of ocular clinical symptoms</measure>
    <time_frame>Change from Baseline to 1 month</time_frame>
    <description>Assessed by SPEED questionnaire, pain score, and dry eye workshop grading</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy in terms of corneal nerve regeneration</measure>
    <time_frame>Change from Baseline to 3 month</time_frame>
    <description>Assessed by corneal topography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy in terms of ocular surface integrity</measure>
    <time_frame>Change from Baseline to 3 month</time_frame>
    <description>Assessed by in vivo confocal microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy in terms of corneal sensitivity</measure>
    <time_frame>Change from Baseline to 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy in terms of ocular clinical symptoms</measure>
    <time_frame>Change from Baseline to 3 month</time_frame>
    <description>Assessed by SPEED questionnaire, pain score, and dry eye workshop grading</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects receiving cryopreserved amniotic membrane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cryopreserved amniotic membrane</intervention_name>
    <description>subjects will receive cryopreserved amniotic membrane</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>ProKera Slim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with moderate to severe DED (Grade 2-4 DEWS)

          -  Age range: 21 years and older.

          -  Both genders and all ethnic groups comparable with the local community.

          -  Subjects able to understand and willing to sign a written informed consent.

          -  Subjects able and willing to cooperate with investigational plan.

          -  Subjects able and willing to complete postoperative follow-up.

        Exclusion Criteria:

          -  Symblepharon or lid abnormality preventing ProKera placement.

          -  Ocular infection within 14 days prior to study entry.

          -  Active ocular allergies.

          -  Previous ocular surgery or injury within 3 months before enrollment.

          -  Previous brain surgery, or Trigeminal nerve damage.

          -  Other conditions that may affect corneal nerves such as diabetes, thyroid disorders.

          -  Contact lens wearers.

          -  Pregnancy or subject expecting to be pregnant.

          -  Inability or unwillingness of subject to give written informed consent.

          -  Subjects with known intolerance to PK.

          -  Subjects use concomitant therapy that affects tear functions or ocular surface
             integrity.

          -  Subjects currently engaged in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas John, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas John Vision Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas John Vision Institute, P.C.</name>
      <address>
        <city>Tinley Park</city>
        <state>Illinois</state>
        <zip>60477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

